A U.S. appeals court has reversed a ban on sales of alirocumab (Praluent), the PCSK9 cholesterol-lowering drug from Regeneron and Sanofi, Reuters reports. The move is seen as a setback for Amgen, which claimed Praluent infringed on patents of its rival drug evolocumab (Repatha). In January, a judge had blocked sales of Praluent following a jury decision in favor of Amgen, but sales continued through the appeals process.